Ask AI
ADA 2026 obesity studies

CE / CME

Translating Emerging Obesity Evidence Into Clinical Action: Highlights From ADA 2026

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: July 21, 2026

Expiration: July 20, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Donna H. Ryan, MD, highlights the outcomes and clinical implications of 4 key obesity studies presented at the American Diabetes Association’s 2026 Scientific Sessions (ADA 2026). Learn how retatrutide is further expanding weight loss expectations, oral GLP-1 receptor agonists (RAs) are supporting the cardiometabolic benefits associated with incretin-based therapy, and CagriSema is enhancing our current understanding regarding the biology of obesity.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with obesity do you provide care for in a typical week?

For those who practice in academic or community settings, please indicate your practice setting:

A 48-year-old man with BMI 46 kg/m², hypertension, and obstructive sleep apnea (OSA) asks about obesity data from ADA 2026. You are reviewing which finding is most likely to influence future obesity treatment standards.

Which ADA 2026 dataset should be prioritized?

A 52-year-old woman with BMI 38 kg/m² and prediabetes asks whether ADA 2026 data prove that orforglipron directly improves β-cell function independent of weight loss. You review an ATTAIN-1 analysis by prediabetes status.

What is the best interpretation?

A 50-year-old woman has a BMI 32 kg/m², hypertension, elevated waist circumference, and prediabetes. She asks whether she should wait until her BMI is ≥35 kg/m² before considering an obesity medication.

What is the best response?